Trillium Reports First Quarter 2016 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. SBUX
3. LEVI
4. HUM
5. NVDA
6. STZ
7. CMG
8. ALHC
9. AAPL
10. SPY

Go back to Trillium Reports First Quarter 2016 Financial Results

Trillium Therapeutics (TRIL) Bullish Stance Reiterated at Leerink Following Q1 Update and Into Clinical Data at ASH

May 13, 2016 11:28 AM EDT

Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and $20 price target on Trillium Therapeutics (NASDAQ: TRIL) following its Q1 update. The firm sees the pipeline progressing and is positive ahead of clinical data at American Society of Hematology (ASH), Dec. 3-6,... More